In mid-2026, Boundless Bio completed a merger with Serapha Bio alongside a $230 million private placement to bolster its oncology drug development pipeline. The company narrowed its focus to two key programs: BBI-355, a selective CHK1 inhibitor in Phase 1/2 trials, and BBI-940, a novel Kinesin degrader advancing toward clinical proof-of-concept after preclinical validation. Operational restructuring including workforce reductions was implemented to extend financial runway. However, early clinical data for BBI-940 revealed pharmacokinetic challenges, triggering development reevaluation. Boundless Bio has maintained strong liquidity with over $20 million cash on hand as of June 30, 2026, supporting ongoing trials and strategic initiatives.